<!DOCTYPE html><html><head><link href='https://fonts.googleapis.com/css?family=Spectral' rel='stylesheet'><style>body {    font-family: 'Spectral';font-size: 14px;}</style></head><body><b>Search Term: </b>"hemophilia A" AND ("gene therapy" OR "genome editing" OR "mRNA therapy")<br><b>Date run: </b>2020/01/02<br><br><h2>PubMed Articles</h2> <br><br><b><a href="https://ncbi.nlm.nih.gov/pubmed/30885692">Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial.</a></b><br><b>Journal:</b> Lancet HIV<br><b>Two-year IF:</b> 13.41<br><br><b><a href="https://ncbi.nlm.nih.gov/pubmed/31843008">Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse.</a></b><br><b>Journal:</b> Genome Biol.<br><b>Two-year IF:</b> 12.16<br><br><b><a href="https://ncbi.nlm.nih.gov/pubmed/31127278">Rescue of spinal muscular atrophy mouse models with AAV9-Exon-specific U1 snRNA.</a></b><br><b>Journal:</b> Nucleic Acids Res.<br><b>Two-year IF:</b> 11.14<br><br><b><a href="http://google.com">More Results...</a></b><br><br><h2>Companies</h2> <br><br><b><a href="https://www.linkedin.com/company/spark-therapeutics-inc/about/">Spark Therapeutics, Inc.</a></b><br><br><b><a href="https://www.linkedin.com/company/dimension-therapeutics/about/">Dimension Therapeutics</a></b><br><br><b><a href="https://www.linkedin.com/company/blanchard-y-asociados/about/">LATINABA</a></b><br><br><b><a href="http://google.com">More Results...</a></b><br><br><h2>Patents</h2> <br><br><b><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&p=1&f=G&l=50&d=PTXT&S1=(%22hemophilia+A%22+AND+((%22gene+therapy%22+OR+%22genome+editing%22)+OR+%22mRNA+therapy%22))&OS="hemophilia+A"+AND+("gene+therapy"+OR+"genome+editing"+OR+"mRNA+therapy")&RS=("hemophilia+A"+AND+(("gene+therapy"+OR+"genome+editing")+OR+"mRNA+therapy"))">PD-L1 expressing hematopoietic stem cells and uses</a></b><br><b>Patent date:</b> December 31, 2019<br><br><b><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=2&p=1&f=G&l=50&d=PTXT&S1=(%22hemophilia+A%22+AND+((%22gene+therapy%22+OR+%22genome+editing%22)+OR+%22mRNA+therapy%22))&OS="hemophilia+A"+AND+("gene+therapy"+OR+"genome+editing"+OR+"mRNA+therapy")&RS=("hemophilia+A"+AND+(("gene+therapy"+OR+"genome+editing")+OR+"mRNA+therapy"))">Triggering RNA interference with RNA-DNA and DNA-RNA nanoparticles</a></b><br><b>Patent date:</b> December 31, 2019<br><br><b><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=3&p=1&f=G&l=50&d=PTXT&S1=(%22hemophilia+A%22+AND+((%22gene+therapy%22+OR+%22genome+editing%22)+OR+%22mRNA+therapy%22))&OS="hemophilia+A"+AND+("gene+therapy"+OR+"genome+editing"+OR+"mRNA+therapy")&RS=("hemophilia+A"+AND+(("gene+therapy"+OR+"genome+editing")+OR+"mRNA+therapy"))">Anti-erythropoietin antibodies</a></b><br><b>Patent date:</b> December 24, 2019<br><br><b><a href="http://google.com">More Results...</a></b><br><br><br><b><a href="http://google.com">Link to Full Search Results</a></b><br><body><html>